Yubo International Biotech Ltd.
About Yubo International Biotech Ltd. Yubo International Biotech Ltd. engages in the supply of products that process, store, and administer therapeutic doses of endometrial stem cells for the ...
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
On Oct. 14, 2026, YBGJ is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Its market capitalization is not available, so no size classification is given.
A per-ticker accuracy statistic for YBGJ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, YBGJ included.
Follow YBGJ free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | YBGJ | Rank |
|---|---|---|
| EPS | $-0.01 | – |
| Metric | YBGJ | Rank |
|---|---|---|
| ROA | -87.6% | 22/24 |
| ROIC | 43.9% | 1/23 |
| Tax Rate | 0.0% | – |
| Metric | YBGJ | Rank |
|---|---|---|
| Current Ratio | 0.18x | 29/30 |
| Quick Ratio | 0.17x | 28/29 |
| Interest Coverage | 7298.4x | 1/30 |
| Working Capital | -$3M | 28/29 |
| Metric | YBGJ | Rank |
|---|---|---|
| Operating Cash Flow | -$780K | 13/30 |
| Metric | YBGJ | Rank |
|---|---|---|
| Asset Turnover | 0.01x | 19/19 |
| Receivables Turnover | 0.1x | 20/20 |
| Inventory Turnover | 0.2x | 27/27 |
| Fixed Assets Turnover | 0.7x | 20/20 |
| Days Sales Outstanding | 4079 days | 1/20 |
| Days Inventory | 2162 days | 1/27 |
| Payables Period | 113947 days | 1/24 |
| Cash Conversion Cycle | -107706 days | 19/19 |
| Metric | YBGJ | Rank |
|---|---|---|
| Total Revenue | $0.00M | 19/19 |
| Operating Income | $0.00M | 10/30 |
| Net Income | $0.00M | 11/24 |
| Cost of Goods Sold | $0.00M | 27/27 |
| Metric | YBGJ | Rank |
|---|---|---|
| EPS Growth | -192.3% | 7/7 |
| Total Current Assets | $580K | |
| Cash & Short-term Investments | $10K | |
| Accounts Receivable | $140K | |
| Inventory | $20K | |
| Total Liabilities | $5M | |
| Short-term Debt | $2M |
Companies classified under the same SEC industry code as Yubo International Biotech Ltd (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| VASO Vaso Corp | ▲ | $51M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▶ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▼ | $3M |
| NUWE Nuwellis, Inc. | ▶ | $2M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▶ | $1M |
| HCIL Hongchang International Co., Ltd | ▶ | N/A |
About Yubo International Biotech Ltd. Yubo International Biotech Ltd. engages in the supply of products that process, store, and administer therapeutic doses of endometrial stem cells for the ...
Yubo International Biotech Ltd. Annual cash flow by MarketWatch. View YBGJ net cash flow, operating cash flow, operating expenses and cash dividends.
Yubo International Biotech Ltd. Annual stock financials by MarketWatch. View the latest YBGJ financial statements, income statements and financial ratios.
On Oct. 14, 2026, YBGJ is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
A per-ticker accuracy statistic for YBGJ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Yubo International Biotech Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
32 issuers in our coverage, YBGJ included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.